Entry Rationale
Given the price's position between a solid support at $74.89 and resistance at $86.45, we saw upside potential toward the resistance on the back of strong earnings momentum and thus considered an entry.
Cytokinetics GAAP EPS of -$1.50 beats by $0.14, revenue of $28.6M beats by $11.14M
Cytokinetics reported GAAP EPS of -$1.50 and revenue of $28.6 million, both exceeding expectations.
Given the price's position between a solid support at $74.89 and resistance at $86.45, we saw upside potential toward the resistance on the back of strong earnings momentum and thus considered an entry.
Based on the current price, if the stock moves upward and reaches the resistance level of $86.45, we will take profit; if it moves downward and breaks below the support level of $74.89, we will implement a stop‑loss.
At the entry point, technical indicators show an RSI(14) of 45.4, moving averages in a bullish alignment, trading volume at 0.92 times the 20‑day average, and a recent 7‑day change of –2.2%.
Initially, based on the positive news of GAAP EPS and revenue exceeding expectations and a solid support level at $74.89, we anticipated an upward trend and projected a target return of 4.5%. However, the actual result was a loss of -11.4%, leading to a FAILED rating. Despite positive indicators at entry—such as an RSI(14) of 45.4, a bullish moving‑average alignment, and better‑than‑expected earnings—the stock price broke below the support level and hit the stop‑loss line. This shows that the favorable news and technical indicators were unable to withstand short‑term downward pressure or selling pressure.
Through this failure, we confirmed that earnings surprises and technical indicators (bullish alignment, support line) do not fully guarantee short-term stock price direction. In future trading, we will reduce overconfidence in positive news, and apply a stricter stop‑loss management strategy to prepare for unexpected volatility, taking into account whether trading volume accompanies the move, and we will reflect this execution strategy in our next trade.